Analyst ahead of ALK report: Focus will be on 2022 prognosis
Allergy company ALK will showcase relatively high R&D costs and will likely also report of increasing marketing expenses in tomorrow’s financial report, says an analyst from Sydbank.
by marketwire, translated by daniel pedersen
Sales growth of ALK’s allergy tablets alongside the 2022 guidance will be center stage tomorrow, when the allergy company publicizes its full-year financial report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK upgrades guidance after positive Q3 report
For subscribers
ALK still has two horses in adrenaline race
For subscribers
